Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
The closing price of CRISPR Therapeutics AG (NASDAQ: CRSP) was $54.13 for the day, down -0.35% from the previous closing price of $54.32. In other words, the price has decreased by -$0.35 from its previous closing price. On the day, 1.49 million shares were traded. CRSP stock price reached its highest trading level at $55.13 during the session, while it also had its lowest trading level at $53.6801.
Ratios:
Our analysis of CRSP’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 16.61 and its Current Ratio is at 16.61. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.12.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Evercore ISI on February 14, 2025, Upgraded its rating to Outperform and sets its target price to $99 from $60 previously.
On February 12, 2025, TD Cowen Upgraded its rating to Hold which previously was Sell but kept the price unchanged to $35. On February 03, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $65.H.C. Wainwright initiated its Buy rating on February 03, 2025, with a $65 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 18 ’25 when Kulkarni Samarth sold 13,081 shares for $58.15 per share. The transaction valued at 760,660 led to the insider holds 207,004 shares of the business.
Treco Douglas A bought 20,000 shares of CRSP for $1,140,600 on Aug 06 ’25. The Director now owns 22,000 shares after completing the transaction at $57.03 per share. On Jul 16 ’25, another insider, George Simeon, who serves as the Director of the company, bought 989,812 shares for $52.03 each. As a result, the insider paid 51,499,918 and bolstered with 1,730,179 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRSP now has a Market Capitalization of 4923145216 and an Enterprise Value of 3417361408. For the stock, the TTM Price-to-Sale (P/S) ratio is 129.39 while its Price-to-Book (P/B) ratio in mrq is 2.80. Its current Enterprise Value per Revenue stands at 89.812 whereas that against EBITDA is -7.816.
Stock Price History:
The Beta on a monthly basis for CRSP is 1.81, which has changed by 0.12209785 over the last 52 weeks, in comparison to a change of 0.14460516 over the same period for the S&P500. Over the past 52 weeks, CRSP has reached a high of $71.13, while it has fallen to a 52-week low of $30.04. The 50-Day Moving Average of the stock is -1.07%, while the 200-Day Moving Average is calculated to be 20.04%.
Shares Statistics:
CRSP traded an average of 3.30M shares per day over the past three months and 2886500 shares per day over the past ten days. A total of 88.38M shares are outstanding, with a floating share count of 86.10M. Insiders hold about 5.33% of the company’s shares, while institutions hold 77.10% stake in the company. Shares short for CRSP as of 1753920000 were 23446400 with a Short Ratio of 7.11, compared to 1751241600 on 25542468. Therefore, it implies a Short% of Shares Outstanding of 23446400 and a Short% of Float of 30.070000000000004.
Earnings Estimates
The performance of CRISPR Therapeutics AG (CRSP) in the stock market is under the watchful eye of 13.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$1.09, with high estimates of $0.16 and low estimates of -$1.63.
Analysts are recommending an EPS of between -$4.16 and -$7.33 for the fiscal current year, implying an average EPS of -$6.12. EPS for the following year is -$4.64, with 17.0 analysts recommending between -$2.25 and -$6.71.
Revenue Estimates
A total of 22 analysts have provided revenue estimates for CRSP’s current fiscal year. The highest revenue estimate was $128.26M, while the lowest revenue estimate was $1.76M, resulting in an average revenue estimate of $35.45M. In the same quarter a year ago, actual revenue was $37.31M
